Skip to main content
Erschienen in: Archives of Virology 12/2011

01.12.2011 | Original Article

UL74 of human cytomegalovirus reduces the inhibitory effect of gH-specific and gB-specific antibodies

verfasst von: Xiao Jing Jiang, Kerstin Laib Sampaio, Nicole Ettischer, York-Dieter Stierhof, Gerhard Jahn, Barbara Kropff, Michael Mach, Christian Sinzger

Erschienen in: Archives of Virology | Ausgabe 12/2011

Einloggen, um Zugang zu erhalten

Abstract

The human cytomegalovirus (HCMV) glycoproteins gH (UL75) and gL (UL115) can form complexes with gO (UL74) or with proteins of the UL128-UL131A locus. Deletion of gO abolishes cell-free virus transmission and renders cell-associated virus transmission in fibroblasts more sensitive to inhibition by human anti-HCMV serum. To test whether the latter effect is specific for gO, we compared mutants with deletions in UL74, UL99 and the UL128-131A locus regarding their sensitivity to anti-HCMV antibodies. UL74 deletion mutants were more sensitive to a further restriction by polyspecific or gH-specific antibodies than control mutants, showing that gO specifically protects focal growth against inhibitory antibodies. This effect was not confined to gH-specific antibodies, as UL74 deletion mutants were also inhibited by an anti-gB antibody. In conclusion, gO specifically promotes focal spread in the presence of gH and gB antibodies, thus contributing to the ability of HCMV to resist the host’s immune response.
Literatur
1.
Zurück zum Zitat Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C, Koszinowski U (2006) Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol 87:2451–2460PubMedCrossRef Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C, Koszinowski U (2006) Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol 87:2451–2460PubMedCrossRef
2.
Zurück zum Zitat Akahori Y, Suzuki K, Daikoku T, Iwai M, Yoshida Y, Asano Y, Kurosawa Y, Shiraki K (2009) Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H. J Virol 83:2020–2024PubMedCrossRef Akahori Y, Suzuki K, Daikoku T, Iwai M, Yoshida Y, Asano Y, Kurosawa Y, Shiraki K (2009) Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H. J Virol 83:2020–2024PubMedCrossRef
3.
Zurück zum Zitat Banks T, Huo B, Kousoulas K, Spaete R, Pachl C, Pereira L (1989) A major neutralizing domain maps within the carboxyl-terminal half of the cleaved cytomegalovirus B glycoprotein. J Gen Virol 70(Pt 4):979–985PubMedCrossRef Banks T, Huo B, Kousoulas K, Spaete R, Pachl C, Pereira L (1989) A major neutralizing domain maps within the carboxyl-terminal half of the cleaved cytomegalovirus B glycoprotein. J Gen Virol 70(Pt 4):979–985PubMedCrossRef
4.
Zurück zum Zitat Borza CM, Hutt-Fletcher LM (2002) Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med 8:594–599PubMedCrossRef Borza CM, Hutt-Fletcher LM (2002) Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med 8:594–599PubMedCrossRef
5.
Zurück zum Zitat Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L et al (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant [see comments]. Blood 86:3598–3603PubMed Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L et al (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant [see comments]. Blood 86:3598–3603PubMed
6.
Zurück zum Zitat Britt WJ (1984) Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology 135:369–378PubMedCrossRef Britt WJ (1984) Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology 135:369–378PubMedCrossRef
7.
Zurück zum Zitat Cranage MP, Kouzarides T, Bankier AT, Satchwell S, Weston K, Tomlinson P, Barrell B, Hart H, Bell SE, Minson AC et al (1986) Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO J 5:3057–3063PubMed Cranage MP, Kouzarides T, Bankier AT, Satchwell S, Weston K, Tomlinson P, Barrell B, Hart H, Bell SE, Minson AC et al (1986) Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO J 5:3057–3063PubMed
8.
Zurück zum Zitat Cui X, Meza BP, Adler SP, McVoy MA (2008) Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26:5760–5766PubMedCrossRef Cui X, Meza BP, Adler SP, McVoy MA (2008) Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26:5760–5766PubMedCrossRef
9.
Zurück zum Zitat Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, Wagner M, Gallina A, Milanesi G, Koszinowski U, Baldanti F, Gerna G (2004) Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78:10023–10033PubMedCrossRef Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, Wagner M, Gallina A, Milanesi G, Koszinowski U, Baldanti F, Gerna G (2004) Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78:10023–10033PubMedCrossRef
10.
Zurück zum Zitat Huber MT, Compton T (1998) The human cytomegalovirus UL74 gene encodes the third component of the glycoprotein H-glycoprotein L-containing envelope complex. J Virol 72:8191–8197PubMed Huber MT, Compton T (1998) The human cytomegalovirus UL74 gene encodes the third component of the glycoprotein H-glycoprotein L-containing envelope complex. J Virol 72:8191–8197PubMed
11.
Zurück zum Zitat Jiang XJ, Adler B, Sampaio KL, Digel M, Jahn G, Ettischer N, Stierhof YD, Scrivano L, Koszinowski U, Mach M, Sinzger C (2008) UL74 of human cytomegalovirus contributes to virus release by promoting secondary envelopment of virions. J Virol 82:2802–2812PubMedCrossRef Jiang XJ, Adler B, Sampaio KL, Digel M, Jahn G, Ettischer N, Stierhof YD, Scrivano L, Koszinowski U, Mach M, Sinzger C (2008) UL74 of human cytomegalovirus contributes to virus release by promoting secondary envelopment of virions. J Virol 82:2802–2812PubMedCrossRef
12.
Zurück zum Zitat Kinzler ER, Compton T (2005) Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J Virol 79:7827–7837PubMedCrossRef Kinzler ER, Compton T (2005) Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J Virol 79:7827–7837PubMedCrossRef
13.
Zurück zum Zitat Lipson SM, Shepp DH, Match ME, Axelrod FB, Whitbread JA (2001) Cytomegalovirus infectivity in whole blood following leukocyte reduction by filtration. Am J Clin Pathol 116:52–55PubMedCrossRef Lipson SM, Shepp DH, Match ME, Axelrod FB, Whitbread JA (2001) Cytomegalovirus infectivity in whole blood following leukocyte reduction by filtration. Am J Clin Pathol 116:52–55PubMedCrossRef
14.
Zurück zum Zitat Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, Lanzavecchia A (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84:1005–1013PubMedCrossRef Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, Lanzavecchia A (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84:1005–1013PubMedCrossRef
15.
Zurück zum Zitat Masuho Y, Matsumoto Y, Sugano T, Fujinaga S, Minamishima Y (1987) Human monoclonal antibodies neutralizing human cytomegalovirus. J Gen Virol 68(Pt 5):1457–1461PubMedCrossRef Masuho Y, Matsumoto Y, Sugano T, Fujinaga S, Minamishima Y (1987) Human monoclonal antibodies neutralizing human cytomegalovirus. J Gen Virol 68(Pt 5):1457–1461PubMedCrossRef
16.
Zurück zum Zitat Paterson DA, Dyer AP, Milne RS, Sevilla-Reyes E, Gompels UA (2002) A role for human cytomegalovirus glycoprotein O (gO) in cell fusion and a new hypervariable locus. Virology 293:281–294PubMedCrossRef Paterson DA, Dyer AP, Milne RS, Sevilla-Reyes E, Gompels UA (2002) A role for human cytomegalovirus glycoprotein O (gO) in cell fusion and a new hypervariable locus. Virology 293:281–294PubMedCrossRef
17.
Zurück zum Zitat Patrone M, Secchi M, Bonaparte E, Milanesi G, Gallina A (2007) Cytomegalovirus UL131-128 products promote gB conformational transition and gB-gH interaction during entry in endothelial cells. J Virol 81:11479–11488 Patrone M, Secchi M, Bonaparte E, Milanesi G, Gallina A (2007) Cytomegalovirus UL131-128 products promote gB conformational transition and gB-gH interaction during entry in endothelial cells. J Virol 81:11479–11488
18.
Zurück zum Zitat Qadri I, Navarro D, Paz P, Pereira L (1992) Assembly of conformation-dependent neutralizing domains on glycoprotein B of human cytomegalovirus. J Gen Virol 73(Pt 11):2913–2921PubMedCrossRef Qadri I, Navarro D, Paz P, Pereira L (1992) Assembly of conformation-dependent neutralizing domains on glycoprotein B of human cytomegalovirus. J Gen Virol 73(Pt 11):2913–2921PubMedCrossRef
19.
Zurück zum Zitat Ryckman BJ, Chase MC, Johnson DC (2010) Human cytomegalovirus TR strain glycoprotein O acts as a chaperone promoting gH/gL incorporation into virions but is not present in virions. J Virol 84:2597–2609PubMedCrossRef Ryckman BJ, Chase MC, Johnson DC (2010) Human cytomegalovirus TR strain glycoprotein O acts as a chaperone promoting gH/gL incorporation into virions but is not present in virions. J Virol 84:2597–2609PubMedCrossRef
20.
Zurück zum Zitat Ryckman BJ, Rainish BL, Chase MC, Borton JA, Nelson JA, Jarvis MA, Johnson DC (2008) Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 82:60–70PubMedCrossRef Ryckman BJ, Rainish BL, Chase MC, Borton JA, Nelson JA, Jarvis MA, Johnson DC (2008) Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 82:60–70PubMedCrossRef
21.
Zurück zum Zitat Schoppel K, Hassfurther E, Britt W, Ohlin M, Borrebaeck CA, Mach M (1996) Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 216:133–145PubMedCrossRef Schoppel K, Hassfurther E, Britt W, Ohlin M, Borrebaeck CA, Mach M (1996) Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology 216:133–145PubMedCrossRef
22.
Zurück zum Zitat Scrivano L, Sinzger C, Nitschko H, Koszinowski UH, Adler B (2011) HCMV spread and cell tropism are determined by distinct virus populations. PLoS Pathog 7:e1001256PubMedCrossRef Scrivano L, Sinzger C, Nitschko H, Koszinowski UH, Adler B (2011) HCMV spread and cell tropism are determined by distinct virus populations. PLoS Pathog 7:e1001256PubMedCrossRef
23.
Zurück zum Zitat Shimamura M, Mach M, Britt WJ (2006) Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 80:4591–4600PubMedCrossRef Shimamura M, Mach M, Britt WJ (2006) Human cytomegalovirus infection elicits a glycoprotein M (gM)/gN-specific virus-neutralizing antibody response. J Virol 80:4591–4600PubMedCrossRef
24.
Zurück zum Zitat Silva MC, Schroer J, Shenk T (2005) Human cytomegalovirus cell-to-cell spread in the absence of an essential assembly protein. Proc Natl Acad Sci USA 102:2081–2086PubMedCrossRef Silva MC, Schroer J, Shenk T (2005) Human cytomegalovirus cell-to-cell spread in the absence of an essential assembly protein. Proc Natl Acad Sci USA 102:2081–2086PubMedCrossRef
25.
Zurück zum Zitat Silva MC, Yu QC, Enquist L, Shenk T (2003) Human cytomegalovirus UL99-encoded pp28 is required for the cytoplasmic envelopment of tegument-associated capsids. J Virol 77:10594–10605PubMedCrossRef Silva MC, Yu QC, Enquist L, Shenk T (2003) Human cytomegalovirus UL99-encoded pp28 is required for the cytoplasmic envelopment of tegument-associated capsids. J Virol 77:10594–10605PubMedCrossRef
26.
Zurück zum Zitat Simpson JA, Chow JC, Baker J, Avdalovic N, Yuan S, Au D, Co MS, Vasquez M, Britt WJ, Coelingh KL (1993) Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J Virol 67:489–496PubMed Simpson JA, Chow JC, Baker J, Avdalovic N, Yuan S, Au D, Co MS, Vasquez M, Britt WJ, Coelingh KL (1993) Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J Virol 67:489–496PubMed
27.
Zurück zum Zitat Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, Messerle M, Hengel H, Koszinowski U, Brune W, Adler B (2008) Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen Virol 89:359–368PubMedCrossRef Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, Messerle M, Hengel H, Koszinowski U, Brune W, Adler B (2008) Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen Virol 89:359–368PubMedCrossRef
28.
Zurück zum Zitat Sinzger C, Knapp J, Plachter B, Schmidt K, Jahn G (1997) Quantification of replication of clinical cytomegalovirus isolates in cultured endothelial cells and fibroblasts by a focus expansion assay. J Virol Methods 63:103–112PubMedCrossRef Sinzger C, Knapp J, Plachter B, Schmidt K, Jahn G (1997) Quantification of replication of clinical cytomegalovirus isolates in cultured endothelial cells and fibroblasts by a focus expansion assay. J Virol Methods 63:103–112PubMedCrossRef
29.
Zurück zum Zitat Sinzger C, Mangin M, Weinstock C, Topp MS, Hebart H, Einsele H, Jahn G (2007) Effect of serum and CTL on focal growth of human cytomegalovirus. J Clin Virol 38:112–119PubMedCrossRef Sinzger C, Mangin M, Weinstock C, Topp MS, Hebart H, Einsele H, Jahn G (2007) Effect of serum and CTL on focal growth of human cytomegalovirus. J Clin Virol 38:112–119PubMedCrossRef
30.
Zurück zum Zitat Spector SA, Hsia K, Crager M, Pilcher M, Cabral S, Stempien MJ (1999) Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 73:7027–7030PubMed Spector SA, Hsia K, Crager M, Pilcher M, Cabral S, Stempien MJ (1999) Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 73:7027–7030PubMed
31.
Zurück zum Zitat Stanton RJ, Baluchova K, Dargan DJ, Cunningham C, Sheehy O, Seirafian S, McSharry BP, Neale ML, Davies JA, Tomasec P, Davison AJ, Wilkinson GW (2010) Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest 120:3191–3208PubMedCrossRef Stanton RJ, Baluchova K, Dargan DJ, Cunningham C, Sheehy O, Seirafian S, McSharry BP, Neale ML, Davies JA, Tomasec P, Davison AJ, Wilkinson GW (2010) Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest 120:3191–3208PubMedCrossRef
32.
Zurück zum Zitat Tischer BK, von Einem J, Kaufer B, Osterrieder N (2006) Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40:191–197PubMedCrossRef Tischer BK, von Einem J, Kaufer B, Osterrieder N (2006) Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40:191–197PubMedCrossRef
33.
Zurück zum Zitat Tugizov S, Navarro D, Paz P, Wang Y, Qadri I, Pereira L (1994) Function of human cytomegalovirus glycoprotein B: syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies. Virology 201:263–276PubMedCrossRef Tugizov S, Navarro D, Paz P, Wang Y, Qadri I, Pereira L (1994) Function of human cytomegalovirus glycoprotein B: syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies. Virology 201:263–276PubMedCrossRef
34.
Zurück zum Zitat Urban M, Britt W, Mach M (1992) The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J Virol 66:1303–1311PubMed Urban M, Britt W, Mach M (1992) The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J Virol 66:1303–1311PubMed
35.
Zurück zum Zitat Urban M, Klein M, Britt WJ, Hassfurther E, Mach M (1996) Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 77(Pt 7):1537–1547PubMedCrossRef Urban M, Klein M, Britt WJ, Hassfurther E, Mach M (1996) Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 77(Pt 7):1537–1547PubMedCrossRef
36.
Zurück zum Zitat Utz U, Britt W, Vugler L, Mach M (1989) Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J Virol 63:1995–2001PubMed Utz U, Britt W, Vugler L, Mach M (1989) Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J Virol 63:1995–2001PubMed
37.
Zurück zum Zitat Wang D, Shenk T (2005) Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 102:18153–18158PubMedCrossRef Wang D, Shenk T (2005) Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 102:18153–18158PubMedCrossRef
38.
Zurück zum Zitat Wang D, Yu QC, Schroer J, Murphy E, Shenk T (2007) Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells. Proc Natl Acad Sci USA 104:20037–20042PubMedCrossRef Wang D, Yu QC, Schroer J, Murphy E, Shenk T (2007) Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells. Proc Natl Acad Sci USA 104:20037–20042PubMedCrossRef
39.
Zurück zum Zitat Wille PT, Knoche AJ, Nelson JA, Jarvis MA, Johnson DC (2010) A human cytomegalovirus gO-null mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells. J Virol 84:2585–2596PubMedCrossRef Wille PT, Knoche AJ, Nelson JA, Jarvis MA, Johnson DC (2010) A human cytomegalovirus gO-null mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells. J Virol 84:2585–2596PubMedCrossRef
40.
Zurück zum Zitat Wirtz N, Schader SI, Holtappels R, Simon CO, Lemmermann NA, Reddehase MJ, Podlech J (2008) Polyclonal cytomegalovirus-specific antibodies not only prevent virus dissemination from the portal of entry but also inhibit focal virus spread within target tissues. Med Microbiol Immunol 197:151–158PubMedCrossRef Wirtz N, Schader SI, Holtappels R, Simon CO, Lemmermann NA, Reddehase MJ, Podlech J (2008) Polyclonal cytomegalovirus-specific antibodies not only prevent virus dissemination from the portal of entry but also inhibit focal virus spread within target tissues. Med Microbiol Immunol 197:151–158PubMedCrossRef
41.
Zurück zum Zitat Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF (1999) Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 180:702–707PubMedCrossRef Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF (1999) Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 180:702–707PubMedCrossRef
Metadaten
Titel
UL74 of human cytomegalovirus reduces the inhibitory effect of gH-specific and gB-specific antibodies
verfasst von
Xiao Jing Jiang
Kerstin Laib Sampaio
Nicole Ettischer
York-Dieter Stierhof
Gerhard Jahn
Barbara Kropff
Michael Mach
Christian Sinzger
Publikationsdatum
01.12.2011
Verlag
Springer Vienna
Erschienen in
Archives of Virology / Ausgabe 12/2011
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-011-1105-x

Weitere Artikel der Ausgabe 12/2011

Archives of Virology 12/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.